Received June 01, 2021
Accepted December 29, 2021

Introduction: Stem cells have been identified from various adult sources, including bone marrow, adipose tissue, placenta and so on. Recently, fallopian tube had also been identified as a novel source of therapeutics. However, are stem cells from the fallopian tube mucosa are able to retain prolonged efficacy of proliferation and differentiation is yet to be explored. This forms the basis of the study. Materials and Methods: The stem cells isolated from fallopian tube mucosa were tested for their marker characterization (markers of mesenchymal, pericyte, epithelial, and cell adhesion molecules) at various passages (P1, P3, P5, P10, P15). The proliferation, differentiation (osteoblast and adipocytes), karyotyping was also carried out at both early (P3) and late (P15) passage. Results: Fallopian tube mucosa possesses mesenchymal stem cells, but it does not retain its ability of proliferation and differentiation beyond P15. Conclusion: The study signifies that, though Fallopian tube mucosal MSCs (FT-MMSCs) possess stem cell attributes, it cannot outweigh or be used in parallel to the existing stem cell sources due to its non-retention ability beyond P15, as reported. Since FT-MMSC studies are at its infancy, further in-depth research is warranted to prove FT-MMSCs use for its bench to bedside applications. Furthermore, it could be a culprit in causing tubal inflammation and fallopian tube hyperplasia, thus insisting on its diagnostic importance and insights for the betterment of womenkind.